Physician profile
Ashlyn E Brown
NPI 1336600089
$620.89
in general payments reported to CMS, 2019-2025
15 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.17 · 2024: $336 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $116.95 | 2024 | Evoke |
| Medtronic, INC. | $107.98 | 2024 | Endurant Iis |
| Novo Nordisk INC | $63.93 | 2023-2025 | Wegovy, Ozempic |
| Exact Sciences Corporation | $51.34 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $46.78 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.67 | 2024-2025 | Jardiance, Ofev |
| Sumitomo Pharma America, INC. | $46.15 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $29.79 | 2025 | Arexvy, Trelegy Ellipta |
| Antares Pharma, INC. | $19.88 | 2024 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.67 | 2025 | Xifaxan |
| Ardelyx, INC. | $17.45 | 2025 | Ibsrela |
| Dexcom, INC. | $17.15 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.26 | 2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $14.25 | 2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $8.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlyn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.